MXCT News and Press, MaxCyte Inc. From 09/28/22

Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation ® technology and ExPERT ™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for hemoglobinopathies ROCKVILLE, Md., Sept. 28, 2022 (GLOBE NEWSWIR...

MaxCyte ( NASDAQ: MXCT ) said it relocated its headquarters to Key West Avenue in Rockville, Maryland, within Maryland's I-270 Biotech Corridor. The new 67K square-foot facility increases MaxCyte's in-house manufacturing capacity and research and process developme...

Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local job opportunities. ROCKVILLE, Md., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: M...

ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, dev...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Small Cap Fund was down 18.60% (Institutional Shares) in the second quarter 2022. The economy is slowing, as we...

Image source: The Motley Fool. MaxCyte, Inc. (NASDAQ: MXCT) Q2 2022 Earnings Call Aug 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: MaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript

Call Start: 16:30 Call End: 17:07 MaxCyte, Inc. (MXCT) Q2 2022 Earnings Conference Call August 10, 2022 16:30 ET Company Participants Sean Menarguez - Director of Investor Relations Doug Doerfler - Founder, President & Chief Executive Officer Ron Holt...

MaxCyte press release ( NASDAQ: MXCT ): Q2 GAAP EPS of -$0.08 in-line. Revenue of $9.6M (+35.2% Y/Y) beats by $0.37M . For further details see: MaxCyte GAAP EPS of -$0.08 in-line, revenue of $9.6M beats by $0.37M

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focu...

RGAIA Investment Advisors are an independent, fee-only investment management firm providing wealth management and financial planning for individuals, families, non-profit firms, and corporations of all sizes. Given any recession is bound to be of the traditional variety, there will no...